COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome)

Main Article Content

Mehmet Unal
Tulay Irez


Coronaviruses (CoV) are a large group from the Coronaviridae family that cause a variety of diseases, from the common cold to more serious clinical conditions such as SARS-CoV and MERS-CoV. This pathogen, which has a single chain, positive polarity and enveloped RNA viruses and causes bilateral interstitial pneumonia, has been associated by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The resulting disease was defined as COVID-19. SARS-CoV-2 belongs to the family of β-coronavirus. Studies have reported that SARS-CoV-2 uses membrane-bound ACE2 to access target cells. It is understood that the virus is transmitted from bats to people, from person to person by droplet or by the contact of the sick person with respiratory secretion materials into the mouth, nose and eye mucous membranes of healthy people. The most common clinical findings were fever (87.9%), cough (67.7%), and weakness (38.1%). The exact diagnosis of Covid-19 is based on virus isolation or RT-PCR positivity. The sensitivity of Thorax CT in the diagnosis of Covid-19 is 97%. Most of the treatments applied are symptomatic. Remdesivir, Chloroquine, Arbidol, Kaletra, lopinavir / ritonavir and remdesivir have been proposed as antiviral agents that can be used in Covid-19 therapy. In order to be protected, attention should be paid to social distance, personal hygiene, a healthy lifestyle, a good sleep pattern, regular exercise, adequate and balanced nutrition. Although the outbreak started in China, it is also quite common in Europe and America. As of May 2, 2020, case reports were made from 215 countries. It has been declared as a pandemic by WHO because of its high transmission rate. The situation is of great importance for global public health. In this paper, we have systematically reviewed the SARS-CoV-2 and this report aims to give information about the genetic structure, pathogenic feature, source of infection, routes of transmission, etiopathogenesis, clinical features, diagnosis, treatment and prevention of the virus and to be a reference for future research, measures and treatments. This review aims to investigate the most current trend of COVID-19.

SARS-Cov-2, COVID-19, coronavirus, severe acute respiratory syndrome

Article Details

How to Cite
Unal, M., & Irez, T. (2020). COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome). Asian Journal of Medicine and Health, 18(4), 1-11.
Review Article


Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, et al. Systematic comparison of two animal to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020;12(2):244.

World Health Organization. Situation Reports.
(Accessed 22 Feb 2020)

Sampathkumar P, Temesgen Z, Smith TF, Thompson RL. Sars: Epidemiology, clinical presentation, management and infection control measures. Mayo Clin Proc. 2003;78:882-890.

Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet; 2020.

TC Ministry of Health Reports.

Guzman J. WHO investigating link between coronavirus and rare inflammatory syndrome.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):e26.

Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Riaz Aghad R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–76.
(Published Online 2020 Feb 26)
DOI: 10.1016/j.ijsu.2020.02.034

Jin Y, Yang H, Ji W, Wu W, Chen S, Weiguo Zhang W, Duan G. Virology, epidemiology, pathogenesis and control of COVID-19. Viruses. 2020;12:372.
DOI: 10.3390/v12040372

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet (Lond. Engl.). 2020;395: 565–574.

Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv; 2020.

Li F. Structure, function and evolution of coronavirus spike proteins. Annu. Rev. Virol. 2016;3:237–261.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395(10224):565– 74.

Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv. Virus Res. 2018;100: 163–188.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARSCoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
(Published online 2020 Mar 5)
DOI: 10.1016/j.cell.2020.02.052

Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, Epstein JH, Mazet JK, Hu B, Zhang W, Peng C. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503:535–538.

Chan JF, To KK, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: Lessons from bats and birds. Trends Microbiol. 2013;21:544-55.

Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27(3):325-8.

Alanagreh L, Alzoughool F, Atoum M. The human coronavirus disease COVID-19: Its origin, characteristics and insights into potential drugs and its mechanisms. Pathogens. 2020;9(5):331.

Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARSCoV-2. J Med Virol.; 2020.

Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruse. Nat. Rev. Microbiol. 2019;17:181–192.

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-3.

Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). International Journal of Oral Science. 2020;12:11.

Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q. Saliva: Potential diagnostic value and transmission of 2019-nCoV; 2020.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med.; 2020.

Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27(3):325-8.

Organization WHO. Coronavirus disease 2019 (COVID-19) Situation Report-40; 2020.

Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, a worldwide public health emergency. Rev Clin Esp. 2020;pii:S0014-2565(20)30092-8.
DOI: 10.1016/j.rce.2020.03.001

Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China; 2020.

Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020;18:20.
DOI: 10.18332/tid/119324
eCollection 2020

Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441–7.

Ding D, Zhu C, Yao W. A cured patient with 2019-nCoV pneumonia. Am J Med. 2020;pii:S0002-9343(20)30210-2.
DOI: 10.1016/j.amjmed.2020.02.023

Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol.
DOI: 10.1002/jmv.25722

Lau H, Khosrawipour V, Kocbach P, Mikolajczyk A, Ichii H, Schubert J, Bania J, Khosrawipour T. Internationally lost COVID-19 cases. J Microbiol Immunol Infect. 2020;pii:S1684-1182(20)30073-6.

Roser M, Ritchie H. Coronavirus Disease (COVID-19). Our World in Data; 2020.
[Cited 2020 Mar 10]

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med.; 2020.
DOI: 10.1056/NEJMoa2001316

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19).
[Cited 2020 Mar 10]

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733.
DOI: 10.1056/NEJMoa2001017

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223): 497–506.

Li Z, Wu M, Guo J, Yao J, Liao X, Song S, et al. Caution on kidney dysfunctions of 2019-nCoV patients; 2020.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA; 2020.

Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv; 2020.

Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and prognosis of covid-19 infection: Systematic review and critical appraisal. BMJ. 2020;369:m1328.
DOI: 10.1136/bmj.m1328

Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatrica. 2020;00:1–8.

Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. 2020;16:16.

PRC NHCot. The Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (5th Trial Version); 2020.

Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev. 2020;5:102538.
DOI: 10.1016/j.autrev.2020.102538

Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, Kumar S, Bhattacharyya A, Kumar H, Bansal S, Medhi B. Drug targets for corona virus: A systematic review. Indian J Pharmacol. 2020;52(1):56-65.
DOI: 10.4103/ijp.IJP_115_20
(Epub 2020 Mar 11)

Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that vitamin D supplementation could reduce risk of ınfluenza and COVID-19 ınfections and deaths. Nutrients. 2020;12:988.
DOI: 10.3390/nu12040988

Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Review Chin J Integr Med. 2020;26(4):243-250.
DOI: 10.1007/s11655-020-3192-6
Epub 2020 Feb 17

Phan T. Novel coronavirus: From discovery to clinical diagnostics. Infect Genet Evol. 2020;79:104211.

Chang L, Yan Y, Wang L. Coronavirus disease 2019: Coronaviruses and blood safety. Transfus Med Rev. 2020;pii: S0887-7963(20)30014-6.
DOI: 10.1016/j.tmrv.2020.02.003

Feng H, Liu Y, Lv M, Zhong J. A case report of COVID-19 with false negative RT-PCR test: Necessity of chest CT. Jpn J Radiol. 2020;38(5):409-410.
DOI: 10.1007/s11604-020-00967-9

Khamitov RA, Loginova S, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol. 2008;53:9-13.

Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: A preliminary study. JAMA. 2003;290:3222-8.

Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73.
DOI: 10.5582/bst.2020.01047
Epub 2020 Feb 19

Yavuz SS, Unal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(SI-1): 611-619.
DOI: 10.3906/sag-2004-145

Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367(6485):1412-1413.
DOI: 10.1126/science.367.6485.1412
PMID: 32217705

Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5):e00399-20.
DOI: 10.1128/AAC.00399-20
Print 2020 Apr 21
PMID: 32152082

Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. Arbidol: A broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15:997-1005.

Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58- 60.
DOI: 10.5582/ddt.2020.01012

Kumar V, Jung YS, Liang PH. Anti-SARS coronavirus agents: A patent review (2008 - present). Expert Opin Ther Pat. 2013;23:1337-48.

Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80-90.

Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676-8.

Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52: 447-56.

Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44-6.

Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis; 2020.
DOI: 10.1016/S1473-3099(20)30120-1